HDL3 stimulates paraoxonase 1 antiatherogenic catalytic and biological activities in a macrophage model system: In vivo and in vitro studies
Authors:
- 10 September 2014
- journal article
- research article
- Published by Wiley in BioFactors
- Vol. 40 (5) , 536-545
Abstract
We analyzed in-vivo and in-vitro high density lipoprotein (HDL) effects on paraoxonase 1 (PON1) antiatherogenic properties in serum and in macrophages. Intraperitoneal injection to C57BL/6 mice of recombinant PON1 (rePON1) + HDL, in comparison to HDL or to rePON1 alone, significantly increased serum PON1 arylesterase activity (by 20%), and serum-mediated cholesterol efflux from J774A.1 macrophages (by 18%). Similarly, in peritoneal macrophages (MPM) harvested from mice injected with HDL + rePON1 versus rePON1 alone, we observed reduction in oxidative stress (by 11%), increase in cellular PON1 activity (by 14%) and in HDL-mediated cholesterol efflux (by 38%). Incubation of serum or HDL with rePON1, substantially increased PON1 arylesterase activity, two-fold more than the expected additive values. HDL2 and HDL3 increased PON1 activity by 199% or 274%, respectively. Macrophage (J774A.1) cholesterol efflux rate significantly increased by HDL3 + rePON1 versus HDL3 alone (by 19%), but not by HDL2 + rePON1 versus HDL2 alone. Oxidation of HDL3 reduced its ability to induce macrophage cholesterol efflux, and abolished HDL3 stimulatory effects on rePON1. Addition of exogenous polyphenol quercetin (60 µM), but not phosphatidylcholine or apolipoprotein A1, to HDL + rePON1 increased PON1 activity (by 404%), increased the ability to reduce oxidative stress in J774A.1 macrophages (by 53%) and to stimulate macrophage cholesterol efflux (by 14%). Upon adding the hypocholesterolemic drug simvastatin (15 µg/mL) to HDL + rePON1, PON1 activity and the ability to induce macrophage cholesterol efflux increased, in comparison to HDL + rePON1. We thus concluded that HDL (mostly HDL3), stimulates PON1 antiatherogenic activities in macrophages, and these PON1 activities were further stimulated by quercetin, or by simvastatin. © 2014 BioFactors, 40(5):536–545, 2014Keywords
Funding Information
- Rappaport family research institute in the Medical Sciences
This publication has 45 references indexed in Scilit:
- Site-specific oxidation of apolipoprotein A-I impairs cholesterol export by ABCA1, a key cardioprotective function of HDLBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- What is a relevant statin concentration in cell experiments claiming pleiotropic effects?British Journal of Clinical Pharmacology, 2011
- In vivo administration of BL-3050: highly stable engineered PON1-HDL complexesBMC Clinical Pharmacology, 2009
- Macrophage paraoxonase 1 (PON1) binding sitesBiochemical and Biophysical Research Communications, 2008
- Distribution Spectrum of Paraoxonase Activity in HDL FractionsClinical Chemistry, 2004
- Decreased Macrophage Paraoxonase 2 Expression in Patients With Hypercholesterolemia Is the Result of Their Increased Cellular Cholesterol Content: Effect of Atorvastatin TherapyArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Human Serum Paraoxonase 1 Decreases Macrophage Cholesterol BiosynthesisArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stressChemical Research in Toxicology, 1992
- Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.Journal of Clinical Investigation, 1990
- Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patientsBiochemical Medicine, 1983